These benefits were largely attributable to subsequent changes in patient management and treatment, which had been guided by the presence of obstructive or nonobstructive coronary artery disease as determined by coronary CTA.
However, it may be that further risk stratification and targeted intensification of therapy in patients with adverse plaque characteristics could achieve additional benefits that go beyond the presence of obstructive or nonobstructive coronary artery disease.
CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed.
This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. As it grows, less blood can flow through the arteries.
Please set your browser to accept cookies to continue.